Barbara Weber, Tango Therapeutics CEO
Daniel O’Day’s I/O dance continues, as Gilead and Tango expand deal up to $6B
Three years ago, Gilead CEO John Milligan signed a milestone-heavy deal with a little-known biotech that had flashy technology and flashier founders. Now, with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.